Claudia F. Baldassano, MD
Assistant Professor of Psychiatry
Staff Psychiatrist
Director
Bipolar Outpatient Clinic
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
|
|
 |
Claudia F. Baldassano, MD
Claudia F. Baldassano, MD, is Assistant Professor of Psychiatry and Staff Psychiatrist at the Hospital of the University of Pennsylvania in Philadelphia, and Director of the Bipolar Outpatient Clinic at the Hospital of the University of Pennsylvania.
Dr. Baldassano received her undergraduate degree at Duke University in Durham, North Carolina. She received her medical degree at Pennsylvania State University College of Medicine in Hershey. Dr. Baldassano completed her internship in Internal Medicine at Pennsylvania Hospital and completed residencies in Psychiatry and in Neurology at Massachusetts General Hospital in Boston. She completed Fellowship training at the Harvard Bipolar Research Program. Her major research interests are Bipolar Disorder, Treatment Refractory Bipolar Depression, and Women Issues in Bipolar Disorder.
Dr. Baldassano has received the Faculty Recognition Award for Teaching and the Annual Teaching Award given by 3rd- and 4th-year Residents. Recently she received a grant from the National Alliance for Schizophrenia and Affective Disorders to evaluate the risk of osteoporosis in women with bipolar disorder. She has coauthored articles for scientific journals such as Expert Review of Neurotherapeutics, American Journal of Psychiatry, Journal of Clinical Psychopharmacology, and Depression. She has also authored and coauthored 4 book chapters.
Statement on Conflict of Interest
It is the policy of The France Foundation that faculty must disclose to activity participants any real or perceived conflict of interest related to the content of their presentations. In addition, all faculty must disclose any discussion of unapproved uses of pharmaceuticals and devices.
Disclosure
Claudia F. Baldassano, MD, serves as a speaker for AstraZeneca Pharmaceuticals and GlaxoSmithKline. She has also received grant and research support from Elan Corporation. GlaxoSmithKline, Janssen Pharmaceutica Products, and Teva Pharmaceutical Industries.
|